Anlon Healthcare IPO Listing: Stock Lists at 1% Premium on NSE

Anlon Healthcare IPO Listing: Shares List with Only 1% Premium — Should Investors Buy, Sell, or Hold?

The much-anticipated initial public offering (IPO) of Anlon Healthcare made a muted debut on the National Stock Exchange (NSE) SME platform on Wednesday, September 3, 2025.

The shares were listed at ₹92, just a 1% premium over the IPO issue price of ₹91 per share.

This lackluster listing performance came as a disappointment to many retail and institutional investors who were hoping for a sharp rally and significant listing gains after the strong subscription numbers in the primary market.

However, when viewed through the lens of pre-listing grey market price (GMP) trends and company fundamentals, the subdued debut was largely anticipated.

The unlisted shares of Anlon Healthcare were trading at around ₹92 in the grey market prior to listing, indicating that the market had already priced in expectations close to the listing price.

In this article, we provide a comprehensive analysis of Anlon Healthcare’s IPO performance, its business model, financial outlook, expert opinions, and what investors should consider before deciding to buy, hold, or sell the shares in the short to medium term.

Strong IPO Subscription Reflects Solid Market Interest

Despite the flat listing, the IPO itself attracted robust demand from investors. Anlon Healthcare’s IPO, which opened for subscription between August 26 and August 29, raised ₹121 crore and was oversubscribed more than 7 times across all investor categories.

The company had fixed a price band of ₹86 to ₹91 per share for its IPO. The final issue price was pegged at the upper end, ₹91, which signals good confidence from investors during the bidding process.

Such oversubscription typically reflects strong institutional and retail interest in the company’s growth prospects, business model, and industry outlook.

However, as the post-listing price action shows, strong IPO subscription does not always translate to immediate listing gains, especially when investors have tempered expectations or when the grey market prices closely track the issue price.

Company Profile: Pharmaceutical Intermediates and APIs Manufacturer

Anlon Healthcare operates in the pharmaceutical sector, focusing on the manufacture of pharmaceutical intermediates and active pharmaceutical ingredients (APIs).

APIs are critical raw materials used in the production of finished pharmaceutical products, and demand for these ingredients is expected to grow globally, driven by the increasing consumption of medicines and healthcare products.

The company claims to be the first producer of loxoprofen and related formulations in India. Loxoprofen is a non-steroidal anti-inflammatory drug (NSAID) widely used for pain relief and inflammation treatment.

Anlon Healthcare’s manufacturing facility is located in Rajkot, Gujarat. The company’s product portfolio and R&D efforts are aligned with global quality standards, which is essential for gaining approvals and entering regulated markets such as Europe, the US, and Brazil.

Utilization of IPO Proceeds

The company plans to deploy the IPO proceeds strategically for growth and balance sheet strengthening:

• Approximately ₹30.7 crore will be used to expand the existing manufacturing facility, which is expected to enhance production capacity and enable the company to serve a larger market.
• Around ₹43.15 crore will be allocated to meet working capital requirements, ensuring smooth operations and timely delivery to customers.
• The remaining funds will be used for repaying existing debt and addressing general corporate needs, which will reduce financial leverage and improve the company’s financial health.

This mix of expansion and debt reduction is generally viewed positively by market participants as it reflects both growth ambitions and prudent financial management.

Financial Performance and Valuation Metrics

As per the company’s financial disclosures, Anlon Healthcare reported moderate revenue growth and profitability trends over recent years.

However, FY24 revenue growth was impacted by regulatory delays related to the company’s efforts to register products in Brazil, one of its target export markets. This temporarily slowed sales momentum but is expected to normalize as the company gains approvals.

On valuation, analysts at Anand Rathi Shares and Stock Brokers note that at the IPO price, the company is valued at a price-to-earnings (P/E) ratio of about 19x based on projected earnings for FY25.

The enterprise value to EBITDA (EV/EBITDA) multiple stands at approximately 16.7x.

While these multiples are not cheap compared to some peers in the pharmaceutical API space, they reflect the company’s small size, growth potential, and the relative stability of the pharmaceutical ingredient industry.

Expert Opinions: Diverse Views for Different Investor Profiles

Narendra Solanki, Head of Fundamental Research, Anand Rathi

“Anlon Healthcare is being valued fairly at the upper price band with a P/E of 19 times FY25 earnings. The company’s business model, focused on niche APIs and intermediates, along with its expansion plans, offers reasonable growth prospects. Investors with a long-term perspective and a moderate risk appetite can consider holding their positions, especially if they believe in the pharmaceutical sector’s growth story.”

Solanki suggests that the stock may not be a quick multibagger but has potential to deliver steady returns if the company executes its plans well.

Shivani Nyati, Wealth Head, Swastika Investmart

“From a cautious perspective, investors should avoid jumping into this stock at current valuations. The company’s heavy reliance on a single manufacturing facility in Rajkot poses operational risks, and its business growth is concentrated in a few products like loxoprofen. Moreover, revenue growth took a hit in FY24 due to registration delays in Brazil, which raises questions on market diversification. Valuation seems high for a relatively small company with execution risks.”

Nyati recommends waiting for clearer signs of consistent revenue growth and geographic diversification before investing.

Harshal Dasani, Business Head, INVasset PMS

“Anlon Healthcare is still a small-scale player in the pharma ingredients sector, but its custom synthesis business model and planned capital expenditure provide opportunities for future growth. That said, this IPO is suitable mainly for investors with a high-risk appetite who can tolerate volatility and are betting on long-term turnaround and expansion.”

Dasani emphasizes the potential upside but warns that near-term performance might be volatile.

Should Investors Buy, Sell, or Hold Anlon Healthcare Shares Now?

For Existing Investors: Hold with Caution

Those who subscribed to the IPO and hold shares should consider holding the stock if they have a long-term investment horizon and can bear short-term volatility.

The company’s growth story is linked to the expanding pharmaceutical ingredients market, and the ongoing capacity expansion could translate to higher revenues and profitability in coming years.

However, investors should monitor quarterly financials closely, especially for progress on registrations, export growth, and any operational risks linked to the company’s single manufacturing unit.

For New Investors: Wait and Watch

New investors considering entering the stock should ideally wait for more clarity on the company’s financial performance post-listing.

If the company shows strong revenue and margin improvement over the next 2-3 quarters, it could justify current valuations.

Until then, valuation concerns and operational concentration risks remain relevant and should be factored into any buy decision.

For Short-Term Traders: Limited Listing Gains

Given the stock listed near its grey market price with only a 1% premium, short-term traders looking for listing gains or quick profits may find limited opportunity here.

The subdued listing indicates that the market is cautious and already factored in the IPO demand and company fundamentals.

Final houghts: A Mixed Bag with Long-Term Potential

Anlon Healthcare’s IPO was a well-subscribed issue reflecting investor interest in the pharmaceutical API space, but the stock’s flat listing dampened immediate enthusiasm.

The company’s growth prospects, driven by manufacturing expansion and new product registrations, offer potential, but execution risks and valuation concerns temper expectations.

Ultimately, Anlon Healthcare may suit investors with a long-term view and moderate to high-risk tolerance, while risk-averse or short-term investors should remain cautious.

As always, investors should conduct their own due diligence, stay updated on company developments, and consult financial advisors before making investment decisions.